171 related articles for article (PubMed ID: 20514406)
1. JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration.
Mendes KN; Wang GK; Fuller GN; Zhang W
Int J Oncol; 2010 Jul; 37(1):143-53. PubMed ID: 20514406
[TBL] [Abstract][Full Text] [Related]
2. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility.
Wang GK; Hu L; Fuller GN; Zhang W
J Biol Chem; 2006 May; 281(20):14085-91. PubMed ID: 16569642
[TBL] [Abstract][Full Text] [Related]
3. Novel anti IGFBP2 single chain variable fragment inhibits glioma cell migration and invasion.
Patil SS; Railkar R; Swain M; Atreya HS; Dighe RR; Kondaiah P
J Neurooncol; 2015 Jun; 123(2):225-35. PubMed ID: 25944386
[TBL] [Abstract][Full Text] [Related]
4. IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma.
Liu Y; Li F; Yang YT; Xu XD; Chen JS; Chen TL; Chen HJ; Zhu YB; Lin JY; Li Y; Xie XM; Sun XL; Ke YQ
Oncogene; 2019 Mar; 38(11):1815-1831. PubMed ID: 30368528
[TBL] [Abstract][Full Text] [Related]
5. COX-2 inhibitors suppress integrin alpha5 expression in human lung carcinoma cells through activation of Erk: involvement of Sp1 and AP-1 sites.
Han S; Roman J
Int J Cancer; 2005 Sep; 116(4):536-46. PubMed ID: 15825163
[TBL] [Abstract][Full Text] [Related]
6. Glioma cell dispersion is driven by α5 integrin-mediated cell-matrix and cell-cell interactions.
Blandin AF; Noulet F; Renner G; Mercier MC; Choulier L; Vauchelles R; Ronde P; Carreiras F; Etienne-Selloum N; Vereb G; Lelong-Rebel I; Martin S; Dontenwill M; Lehmann M
Cancer Lett; 2016 Jul; 376(2):328-38. PubMed ID: 27063097
[TBL] [Abstract][Full Text] [Related]
7. Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line.
Kita D; Takino T; Nakada M; Takahashi T; Yamashita J; Sato H
Cancer Res; 2001 Nov; 61(21):7985-91. PubMed ID: 11691823
[TBL] [Abstract][Full Text] [Related]
8. Regulation of β-catenin by IGFBP2 and its cytoplasmic actions in glioma.
Verma BK; Kondaiah P
J Neurooncol; 2020 Sep; 149(2):209-217. PubMed ID: 32803659
[TBL] [Abstract][Full Text] [Related]
9. Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1.
Martino-Echarri E; Fernández-Rodríguez R; Bech-Serra JJ; Plaza-Calonge Mdel C; Vidal N; Casal C; Colomé N; Seoane J; Canals F; Rodríguez-Manzaneque JC
Oncotarget; 2014 Jun; 5(12):4295-304. PubMed ID: 24962328
[TBL] [Abstract][Full Text] [Related]
10. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
Myers AL; Lin L; Nancarrow DJ; Wang Z; Ferrer-Torres D; Thomas DG; Orringer MB; Lin J; Reddy RM; Beer DG; Chang AC
Oncotarget; 2015 Sep; 6(28):25897-916. PubMed ID: 26317790
[TBL] [Abstract][Full Text] [Related]
11. IGFBP2 potentiates nuclear EGFR-STAT3 signaling.
Chua CY; Liu Y; Granberg KJ; Hu L; Haapasalo H; Annala MJ; Cogdell DE; Verploegen M; Moore LM; Fuller GN; Nykter M; Cavenee WK; Zhang W
Oncogene; 2016 Feb; 35(6):738-47. PubMed ID: 25893308
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network.
Holmes KM; Annala M; Chua CY; Dunlap SM; Liu Y; Hugen N; Moore LM; Cogdell D; Hu L; Nykter M; Hess K; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2012 Feb; 109(9):3475-80. PubMed ID: 22345562
[TBL] [Abstract][Full Text] [Related]
13. Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies.
Phillips LM; Zhou X; Cogdell DE; Chua CY; Huisinga A; R Hess K; Fuller GN; Zhang W
J Pathol; 2016 Jul; 239(3):355-64. PubMed ID: 27125842
[TBL] [Abstract][Full Text] [Related]
14. Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Niibori-Nambu A; Midorikawa U; Mizuguchi S; Hide T; Nagai M; Komohara Y; Nagayama M; Hirayama M; Kobayashi D; Tsubota N; Takezaki T; Makino K; Nakamura H; Takeya M; Kuratsu J; Araki N
PLoS One; 2013; 8(5):e59558. PubMed ID: 23704872
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids increase alpha5 integrin expression and adhesion of synovial fibroblasts but inhibit ERK signaling, migration, and cartilage invasion.
Lowin T; Straub RH; Neumann E; Bosserhoff A; Vogel C; Moissl C; Anders S; Müller-Ladner U; Schedel J
Arthritis Rheum; 2009 Dec; 60(12):3623-32. PubMed ID: 19950288
[TBL] [Abstract][Full Text] [Related]
16. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Han S; Li Z; Master LM; Master ZW; Wu A
Br J Cancer; 2014 Sep; 111(7):1400-9. PubMed ID: 25093489
[TBL] [Abstract][Full Text] [Related]
17. Expression of insulin-like growth factor binding protein genes and its hypoxic regulation in U87 glioma cells depends on ERN1 mediated signaling pathway of endoplasmic reticulum stress.
Minchenko DO; Kharkova AP; Karbovskyi LL; Minchenko OH
Endocr Regul; 2015 Apr; 49(2):73-83. PubMed ID: 25960008
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor (TGF) β1 acted through miR-130b to increase integrin α5 to promote migration of colorectal cancer cells.
Yi R; Li Y; Wang F; Gu J; Isaji T; Li J; Qi R; Zhu X; Zhao Y
Tumour Biol; 2016 Aug; 37(8):10763-73. PubMed ID: 26873488
[TBL] [Abstract][Full Text] [Related]
19. Impact of integrin-matrix interaction and signaling on insulin gene expression and the mesenchymal transition of human beta-cells.
Kaido TJ; Yebra M; Kaneto H; Cirulli V; Hayek A; Montgomery AM
J Cell Physiol; 2010 Jul; 224(1):101-11. PubMed ID: 20232313
[TBL] [Abstract][Full Text] [Related]
20. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
